| Autor: |
R, Shireen, D, Brennan, G, Flannelly, D, Fennelly, P, Lenehan, M, Foley |
| Rok vydání: |
2012 |
| Předmět: |
|
| Zdroj: |
Irish medical journal. 105(2) |
| ISSN: |
0332-3102 |
| Popis: |
Adjuvant chemotherapy regime for ovarian cancer patients remains to be a contentious issue. The aim of this study was to compare the overall and progression-free survival of women with ovarian cancer before and after introduction of paclitaxel in our unit in 1992. A sample of 112 women who received adjuvant therapy following surgery for ovarian cancer was collected, 68 (61%) received platinum+alkylating agent before 1992 and later 44 (39%) received platinum+paclitaxel. Five-year survival was same in both treatment groups when there was no macroscopic disease after surgery (78% versus 70%) and when residual disease was2 cm (50% versus 40%). Survival was greater in women with residual disease2 cm in the platinum+paclitaxel group (50% versus 24%), (p = 0.04). However, progression-free survival was similar in both groups irrespective of stage or residual volume of disease. Therefore consideration to selective use of paclitaxel could reduce patient morbidity and costs significantly. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
